🔎 Trials Near Me

Home › Steatotic Liver Disease › Maryland › Baltimore

Steatotic Liver Disease clinical trials in Baltimore, MD

5 studies for Steatotic Liver Disease are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

RecruitingPhase 3
  • Mercy Medical Center - Baltimore, Baltimore
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07165028

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

RecruitingPhase 3
  • Akero Clinical Study Site, Baltimore
Ages 18 to 80 · All sexes · Updated Sep 21, 2026 · NCT06528314

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

RecruitingPhase 3
  • 89bio Clinical Study Site, Baltimore
  • 89bio Clinical Study Site, Glen Burnie · 9 mi away
Ages 18 to 80 · All sexes · Updated Sep 3, 2026 · NCT06318169

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

RecruitingPhase 3
  • 89bio Clinical Study Site, Baltimore
  • 89bio Clinical Study Site, Glen Burnie · 9 mi away
Ages 18 to 75 · All sexes · Updated Sep 3, 2026 · NCT06419374

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

RecruitingPhase 2
  • GSK Investigational Site, Baltimore
Ages 18 to 75 · All sexes · Updated Jul 8, 2026 · NCT06920043

About Steatotic Liver Disease

Steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. Learn about the causes and treatments.

More about Steatotic Liver Disease on MedlinePlus

Steatotic Liver Disease trials in other cities

Other studies in Baltimore

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.